Randomized Controlled Trial Evaluating Ovulation Response after Myo Inositol versus Metformin in Women with Polycystic Ovary Syndrome.

Manasi  Mohapatra; Binod Bihari  Mishra; Ankita  Pattanaik

doi:10.51168/sjhrafrica.v7i3.2561

Authors

Manasi Mohapatra Assistant Professor, Department of Obstetrics & Gynaecology, DRIEMS Institute of Health Sciences and Hospital, Odisha, India
Binod Bihari Mishra Associate Professor, Department of Obstetrics & Gynaecology, DRIEMS Institute of Health Sciences and Hospital, Odisha, India
Ankita Pattanaik Associate Professor, Department of Obstetrics and Gynaecology, Padmini Care and DRIEMS IHS, Tangi, Odisha, India

DOI:

https://doi.org/10.51168/sjhrafrica.v7i3.2561

Keywords:

Polycystic Ovary Syndrome, Myo-inositol, Metformin, ovulation induction, infertility

Abstract

Background:
One of the most prevalent endocrine conditions affecting women of reproductive age is polycystic ovary syndrome (PCOS), which is a primary contributor to anovulatory infertility. One important factor in the pathophysiology of PCOS is insulin resistance. While myo-inositol has lately surfaced as a viable substitute for enhancing ovulatory function, metformin has long been utilized as an insulin sensitizer.

Objective:
To compare the ovulation response of Myo-inositol and Metformin in women with PCOS.

Methods:
Over the course of four months, 200 women with PCOS were included in a research trial. Two groups of one hundred each were randomly selected from among the participants. Group B was given 500 mg of metformin three times a day, while Group A was given 2 g of myo-inositol twice a day. Follicle monitoring and blood progesterone levels were used to track ovulation. Pregnancy rate, menstrual regularity, and ovulation rate were among the results. The chi-square test was used for statistical analysis, and p <0.05 was deemed statistically significant.

Results:
Compared to 48% of women in the Metformin group, 62% of women in the Myo-inositol group experienced ovulation. Compared to 18% of women taking metformin, 28% of women taking myo-inositol became pregnant. Myo-inositol appeared to improve the difference in ovulation rate (p = 0.064). Although the Myo-inositol group had a greater pregnancy rate, the difference was not statistically significant (p = 0.13).

Conclusion:
In women with PCOS, myo-inositol produced better ovulation and pregnancy outcomes than metformin. For PCOS patients, it can be regarded as an efficient and well-tolerated substitute for ovulation induction.

Recommendation:

Myo-inositol may be considered a preferable first-line therapy for ovulation induction in women with polycystic ovary syndrome due to its favorable efficacy and tolerability profile.

References

Rani C, Deeba F, Ishrat S, Banu J, Jahan S, Nazneen S, et al. Effects of metformin plus myo-inositol compared to metformin alone as pre-treatment of ovulation induction in polycystic ovary syndrome with insulin resistance. Int J Reprod Contraception, Obstet Gynecol. 2022;11(11):3005–11.

Fereshteh Rastegar, Zahra Rezaee, Nafiseh Saedi, Reza Memari MT. Comparison of the Effect of Metformin Versus the Combination of Folic Acid / Myo-inositol in Infertile Women with Polycystic Ovary Syndrome Undergoing In Vitro Fertilization : A Randomized Clinical Trial. Biomed Res Ther. 2021;8(12):4734–9.

Salman, Ahmed M, Fatma M. Sayed, and HMH. Induction cycles prospective cohort study: Effectiveness of myoinositol versus metformin as adjuvant treatment on infertile polycystic ovaries. J Med Sci Res. 2026;9(1):24–30.

Ravn P, Gram F, Andersen MS, Glintborg D. Myoinositol vs Metformin in Women with Polycystic Ovary Syndrome : A Randomized Controlled Clinical Trial. Metabolites. 2022;12(1183):1–10.

Johra TH, Akther N, Rabeya S, Hil A, Khan K, Amanullah M. A Comparative Study of Myoinositol and Metformin for Ovulation Induction in Pregnant Women with PCOS. East African Sch J Med Sci. 2023;6(1):23–9.

Kriplani A, Tank P, Singh P, Maini N, Kaitala S, G LK. A Phase III, Double-Blind, Randomized, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Metformin Hydrochloride and Myo-Inositol Compared to Metformin in Patients With Polycystic Ovary Syndrome. Cureus. 2024;16(12):`1-11.

Aleksandra Gudovi´c, Zoran Bukumiri´c, Milos Milincic KI and SS-R ¯denovi´c. The Comparative Effects of Myo-Inositol and Metformin Therapy on the Clinical and Biochemical Parameters of Women of Normal Weight Suffering from Polycystic Ovary Syndrome. biomedicines. 2024;12(349):1–16.

Raj P, Samal S, Chandrasekaran S, Prabhu K, Sen M. Comparison of Metformin and Myoinositol on Clinical, Hormonal and Metabolic Profile of Patients with Polycystic Ovarian Syndrome : An Open-label Randomised Clinical Trial. J Clin Diagnostic Res. 2024;18(1):18–22.